News | October 14, 2022
Cytel to acquire SDS Life Science and SDS MedteQ
The move will add new global talent to Cytel’s Strategic Consulting group
The move will add new global talent to Cytel’s Strategic Consulting group
Construction is now underway with the facility scheduled to be operational by 2025
NATCO to sell 15% of shareholding in Nativita for euro 3,45,000 to Pharmasyntez-Nord
The acquisition reaffirms Infosys’ commitment to help global life sciences companies
The refocused commercial set-up will increase organizational efficiency and alignment across all commercial functions globally
RSV is the most common viral cause of respiratory tract infections in newborns, young children, older adults, or the immunocompromised
Tirzepatide is primarily indicated for the treatment of T2D and is expected to receive its decision from the FDA in Q2 2022
India has the second-largest number of adults with diabetes globally, after China
According to the brokerage, as the pandemic has receded, the past exceptional growth in acute therapies may not be repeated (stellar double-digit growth for anti-infectives coming down)
In the trial, there was no statistical difference in estimated hypoglycaemia rates, and no severe hypoglycaemia events were observed for people treated with insulin icodec
Subscribe To Our Newsletter & Stay Updated
